These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Against pragmatism: on efficacy, effectiveness and the real world. Kent DM; Kitsios G Trials; 2009 Jul; 10():48. PubMed ID: 19580642 [TBL] [Abstract][Full Text] [Related]
44. Framing the conversation: use of PRECIS-2 ratings to advance understanding of pragmatic trial design domains. Lipman PD; Loudon K; Dluzak L; Moloney R; Messner D; Stoney CM Trials; 2017 Nov; 18(1):532. PubMed ID: 29126437 [TBL] [Abstract][Full Text] [Related]
45. Protocol refinement for a diabetes pragmatic trial using the PRECIS-2 framework. Glasgow RE; Gurfinkel D; Waxmonsky J; Rementer J; Ritchie ND; Dailey-Vail J; Hosokawa P; Dickinson LM; Kwan BM BMC Health Serv Res; 2021 Oct; 21(1):1039. PubMed ID: 34598702 [TBL] [Abstract][Full Text] [Related]
47. Real-world experiences with generating real-world evidence: Case Studies from PCORI's pragmatic clinical Studies program. Neuman MD; Kappelman MD; Israel E; Ellenberg SS; Girman C; Robb J; Rabinowitz A; Trontell A Contemp Clin Trials; 2020 Nov; 98():106171. PubMed ID: 33038503 [TBL] [Abstract][Full Text] [Related]
48. [The PRECIS-2 tool: designing trials that are fit for purpose]. Hu GP; Zhan SY Zhonghua Liu Xing Bing Xue Za Zhi; 2018 Feb; 39(2):222-226. PubMed ID: 29495210 [TBL] [Abstract][Full Text] [Related]
49. Pragmatic trial design elements showed a different impact on trial interpretation and feasibility than explanatory elements. Nieuwenhuis JB; Irving E; Oude Rengerink K; Lloyd E; Goetz I; Grobbee DE; Stolk P; Groenwold RH; Zuidgeest MG; J Clin Epidemiol; 2016 Sep; 77():95-100. PubMed ID: 27164273 [TBL] [Abstract][Full Text] [Related]
50. The PRECIS-2 tool has good interrater reliability and modest discriminant validity. Loudon K; Zwarenstein M; Sullivan FM; Donnan PT; Gágyor I; Hobbelen HJSM; Althabe F; Krishnan JA; Treweek S J Clin Epidemiol; 2017 Aug; 88():113-121. PubMed ID: 28603007 [TBL] [Abstract][Full Text] [Related]
51. The need for more pragmatic trials in glaucoma research. Pacovska MF; de Amorim-Cabral CLD; Teixeira EGDRM; Kasahara N Eur J Ophthalmol; 2024 Apr; ():11206721241247428. PubMed ID: 38602016 [TBL] [Abstract][Full Text] [Related]
52. Explanatory Versus Pragmatic Trials: An Essential Concept in Study Design and Interpretation. Merali Z; Wilson JR Clin Spine Surg; 2017 Nov; 30(9):404-406. PubMed ID: 29049130 [TBL] [Abstract][Full Text] [Related]
53. Designing provider-focused implementation trials with purpose and intent: introducing the PRECIS-2-PS tool. Norton WE; Loudon K; Chambers DA; Zwarenstein M Implement Sci; 2021 Jan; 16(1):7. PubMed ID: 33413489 [TBL] [Abstract][Full Text] [Related]
54. Pragmaticism of Randomized Controlled Trials of Biologic Treatment With Methotrexate in Rheumatoid Arthritis: A Systematic Review. Choi MY; Barnabe C; Barber CE; Bykerk V; Pope JE; Hazlewood GS Arthritis Care Res (Hoboken); 2019 May; 71(5):620-628. PubMed ID: 29908014 [TBL] [Abstract][Full Text] [Related]
55. Informing real-world practice with real-world evidence: the value of PRECIS-2. Neta G; Johnson KE BMC Med; 2018 May; 16(1):76. PubMed ID: 29783964 [TBL] [Abstract][Full Text] [Related]
56. Use of PRECIS ratings in the National Institutes of Health (NIH) Health Care Systems Research Collaboratory. Johnson KE; Neta G; Dember LM; Coronado GD; Suls J; Chambers DA; Rundell S; Smith DH; Liu B; Taplin S; Stoney CM; Farrell MM; Glasgow RE Trials; 2016 Jan; 17():32. PubMed ID: 26772801 [TBL] [Abstract][Full Text] [Related]
57. PRECIS-2 for retrospective assessment of RCTs in systematic reviews. Zwarenstein M; Thorpe K; Treweek S; Loudon K J Clin Epidemiol; 2020 Oct; 126():202-206. PubMed ID: 32565215 [TBL] [Abstract][Full Text] [Related]
58. [Progress in research of pragmatic-explanatory continuum indicator summary]. Hu G; Hu Y; Zhan S Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Mar; 37(3):439-42. PubMed ID: 27005554 [TBL] [Abstract][Full Text] [Related]
59. Series: Pragmatic trials and real world evidence: Paper 6. Outcome measures in the real world. Welsing PM; Oude Rengerink K; Collier S; Eckert L; van Smeden M; Ciaglia A; Nachbaur G; Trelle S; Taylor AJ; Egger M; Goetz I; J Clin Epidemiol; 2017 Oct; 90():99-107. PubMed ID: 28502810 [TBL] [Abstract][Full Text] [Related]
60. Comparison of explanatory and pragmatic design choices in a cluster-randomized hypertension trial: effects on enrollment, participant characteristics, and adherence. Margolis KL; Crain AL; Green BB; O'Connor PJ; Solberg LI; Beran M; Bergdall AR; Pawloski PA; Ziegenfuss JY; JaKa MM; Appana D; Sharma R; Kodet AJ; Trower NK; Rehrauer DJ; McKinney Z; Norton CK; Haugen P; Anderson JP; Crabtree BF; Norman SK; Sperl-Hillen JM Trials; 2022 Aug; 23(1):673. PubMed ID: 35978336 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]